Login to Your Account

NewCo News

Fluorinov Pharma to Develop Oral Multiple Myeloma Drug

By Peter Winter
BioWorld Insight Editor

Friday, June 8, 2012
Following on from the success of the approved first-generation proteasome inhibitor Velcade (bortezomib, Millennium/Takeda Pharmaceutical Co. Ltd.), which jams up the proteasome and nonspecifically inhibits proteins from being degraded, various new proteasome inhibitors are currently in development, including peptide boronic acid analogue MLN9708 (Millennium/Takeda) and carfilzomib (Onyx Pharmaceuticals Inc.).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription